menu search

PEAR / Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript
Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Michael Cherny - Bank of America Charles Rhyee - Cowen Neena Bitritto-Garg - Citi Eric Percher - Nephron Research Keay Nakae - Chardan Judah Frommer - Credit Suisse Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics First Quarter 2022 Earnings Conference Call. Read More
Posted: May 17 2022, 13:52
Author Name: Seeking Alpha
Views: 102411

PEAR News  

Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?

By InvestorPlace
April 14, 2023

Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?

Pear Therapeutics (NASDAQ: PEAR ) stock is falling on Friday after the company's recent bankruptcy filing continues to weigh on its shares. Pear Thera more_horizontal

Why Is Pear Therapeutics (PEAR) Stock Up 21% Today?

By InvestorPlace
March 21, 2023

Why Is Pear Therapeutics (PEAR) Stock Up 21% Today?

Pear Therapeutics (NASDAQ: PEAR ) stock is climbing higher on Tuesday despite the company's plans to explore strategic alternatives. That news was fir more_horizontal

Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
January 19, 2023

Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this more_horizontal

Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 14, 2022

Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript

Pear Therapeutics Inc. (NASDAQ:PEAR ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Direc more_horizontal

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 17, 2022

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript

Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of more_horizontal

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 28, 2022

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript more_horizontal

Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months

By Benzinga
March 15, 2022

Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months

Pear Therapeutics Inc (NASDAQ: PEAR) announced data that further underscore the effectiveness of Somryst for chronic insomnia at the World Sleep 2022 more_horizontal


Search within

Pages Search Results: